Profile of Cognitive Impairement in Patients with Brain Tumors in Dr. Moewardi Hospital, Surakarta
Abstract
Background: Brain tumor is a disease that is difficult to treat and causes high morbidity and morta¬lity. One of the clinical manifestations of brain tumors is cognitive impairment which is the most common neurological problem. The aim of this study is to determine the profile of cognitive impairment in patients with brain tumors.
Subjects and Method: The design of this study was a retrospective cross-sectional using secondary data from the Neurology Polyclinic of RSUD Dr. Moewardi in January 2021-March 2022. The subject was diagnosed with a brain tumor based on anamnesis, physical examination, and neuroimaging. Cognitive impairment was inferred through the MoCA-Ina test. The analysis used was univariate descriptive analysis, independent T test, Mann-Whitney test, and Pearson correlation test.
Results: There were 29 subjects with a mean MoCA-Ina score (17.97). Primary brain tumors (79.3%), more than metastatic tumors. The majority of patients were diagnosed with meningioma (55.2%). This study showed that there were differences in abstraction scores (p=0.015) and total MoCA-Ina scores (p=0.042) between patients with tumors located in the temporal lobe and non- temporal lobe; differences in abstraction scores (p=0.034) and orientation scores (p=0.042) between patients with supratentorial and infratentorial tumors; and differences in memory scores (p=0.028) between patients with and without radiation history. In addition, this study also found an association between the number of lobes affected by brain tumors with attention score (p=0.027; r=-0.409), abstraction score (p=0.004; r=-0.524), orientation score (p=0.021; r=-0.426), and the total score of MoCA-Ina (p=0.018, r=-0.435).
Conclusion: There is an association between brain tumors and cognitive impairment which is concluded through the MoCA-Ina test. The clinical manifestations of cognitive impairment in the patient are in accordance with the neuroanatomical function of the brain affected by the lesion.
Keywords: Cognitive, Tumor, MoCA-Ina
Correspondence: Maria Yosita Ayu Hapsari. Department of Neurology, Faculty of Medicine, Universitas Sebelas Maret/ Moewardi Hospital, Indonesia. Email: ayositahapsari@gmail.com. Phone: 0813 3155 5412.
Indonesian Journal of Medicine (2022), 07(02): 242-250
https://doi.org/10.26911/theijmed.2022.07.02.12
References
Barani IJ, Benedict SH Lin PS (2007). Neural Stem Cells: Implications for the Conventional Radiotherapy of Central Nervous System Malignancies. Int. J. Rad. Oncol. Biol. Phys. 68(2): 324–333. Doi: 10.1016/j.ijrobp.2007.01.033.
Boake C, Meyers CA. (1993). Brain tumor rehabilitation: Survey of clinical practice. Arch Phys Med Rehabil. 74: 1247.
Fox SW, Mitchell SA, Booth Jones M (2006). Cognitive impairment in patients with brain tumors: assessment and intervention in the clinic setting. Clin. J. Oncol. Nurs. 10(2): 169–176. Doi: 10.1188/06.CJON.169176.
Ghia A, Tomé WA, Thomas S, Cannon G, Khuntia D, Kuo JS, Mehta MP (2007). Distribution of brain metastases in relation to the hippocampus: implications for neurocognitive functional preservation. Int J Radiat Oncol Biol Phys. 68(4):9717. Doi: 10.1016/j.ijrobp.2007.02.016.
Hickey JV, Hock NH (2003). Stroke and other cerebrovascular diseases. The clinical practice of neurological and neurosurgical nursing (5th ed.). Philadelphia: Lippincott, Williams, & Wilkins.
Husein N, Lumempouw S, Ramli Y (2010). Uji Validitas dan Reliabilitas Montreal Cognitive Assessment Versi Indonesia (MoCAIna). Neurona. 27(4): 1–13.
J Strong M, Garces J (2016). Brain Tumors: Epidemiology and Current Trends in Treatment. J. Brain Tumors Neurooncol. 01(01): 1–21. Doi: 10.4172/24753203.1000102.
Johnson DR, Guerin JB, Giannini C, Morris JM, Eckel LJ, Kaufmann TJ (2017). 2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know. Radiographics. 37(7):21642180. Doi: 10.1148/rg.2017170037.
Klein M, Taphoorn MJ, Heimans JJ, van der Ploeg HM, Vandertop WP, Smit EF, Leenstra S, et al. (2001). Neurobehavioral status and healthrelated quality of life in newly diagnosed highgrade glioma patients. J Clin Oncol. 19(20):403747. Doi: 10.1200/JCO.2001.19.20.4037.
McNeill KA (2016). Epidemiology of Brain Tumors. Neurol. Clin. 34(4): 981–998. Doi: 10.1016/j.ncl.2016.06.014.
Olson RA, Iverson GL, Carolan H, Parkinson M, Brooks BL, McKenzie M (2011). Prospective comparison of two cognitive screening tests: diagnostic accuracy and correlation with community integration and quality of life. J Neurooncol. 105(2):33744. Doi: 10.1007/s1106001105954.
Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, BarnholtzSloan JS (2015). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 20082012. Neuro Oncol. 17(Suppl 4):iv1iv62. Doi: 10.1093/neuonc/nov189.
GBD 2016 Brain and Other CNS Cancer Collaborators (2019). Global, regional, and national burden of brain and other CNS cancer, 19902016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18(4):376393. Doi: 10.1016/S14744422(18)30468X.
